CIK 0001991792 · Large accelerated filer
CG Oncology, Inc.
Sign in to watch- Ticker
- CGON
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 371611499
- Phone
- (949) 409-3700
- Business address
- 3000 PEGASUS PARK DRIVE, SUITE 1640, DALLAS, TX, 75247
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $135,045
- in 2 filings, $135K under 10b5-1 plans
Net −$135,045. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-29 | Decheng Capital Global Life Sciences Fund IV, L.P. 10% owner | Conversion · Series F Preferred Stock | −4,402,320 | 0 | ||
| 2024-01-29 | Kasturi Vijay Chief Medical Officer | Purchase | +1,315 | $19.00 | $25K | 1,315 |
| 2024-01-29 | Roche Corleen M. CFO & Secretary | Purchase | +2,000 | $19.00 | $38K | 2,000 |
| 2024-01-29 | Song Hong Fang Director | Conversion | +350,771 | 350,771 | ||
| 2024-01-29 | Song Hong Fang Director | Conversion | +1,011,192 | 1,011,192 | ||
| 2024-01-29 | Song Hong Fang Director | Conversion | +3,930,176 | 3,930,176 | ||
| 2024-01-29 | Song Hong Fang Director | Purchase | +263,157 | $19.00 | $5.0M | 613,928 |
| 2024-01-29 | Song Hong Fang Director | Conversion · Series B Preferred Stock | −3,344,608 | 0 | ||
| 2024-01-29 | Song Hong Fang Director | Conversion · Series C Preferred Stock | −6,262,967 | 0 | ||
| 2024-01-29 | Song Hong Fang Director | Conversion · Series D Preferred Stock | −3,378,758 | 0 | ||
| 2024-01-29 | Song Hong Fang Director | Conversion · Series E Preferred Stock | −37,474,236 | 0 | ||
| 2024-01-24 | Roche Corleen M. CFO & Secretary | Grant or award · Stock Option | +492,920 | 492,920 |
Page 9 of 9 · 172 trades